Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31696363 | 0.96 | LMNA (0.54) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL8138183 | 0.78 | CNR2 (0.41) | MAPTAXLNCF1PARP1CNR2 | |
| SCHEMBL3147045 | 0.77 | PIK3CD (0.40) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL31227945 | 0.76 | CNR2 (0.40) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL24898090 | 0.75 | LMNA (0.35) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL1315767 | 0.75 | MAPT (0.53) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30738179 | 0.75 | MAPT (0.53) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL12266517 | 0.74 | LMNA (0.60) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL11214509 | 0.74 | CYP1A2 (0.59) | LMNAAXLPARP1KDM4ESMN1; SMN2 | |
| SCHEMBL30892029 | 0.74 | CYP1A2 (0.59) | LMNACYP3A4MAPTAPEX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079775-B | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-112079775-A | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-1348711-B1 | LUMINESCENT ELEMENT AND DISPLAY | CANON KK (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-1889891-B1 | Luminescence device and display apparatus | CANON KK (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| CN-1474826-A | Light emitting device and display | ������������ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1348711-A1 | LUMINESCENT ELEMENT AND DISPLAY | CANON KABUSHIKI KAISHA (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-20030068526-A1 | Such as tetrakis(1-(5-heptyloxyphenyl)isoquinoline-C2,N) (pu-dichloro) iridium (III); for red luminescence; graphic arts | CANON KABUSHIKI KAISHA (JP) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | LMNA 2968/4885CYP3A4 205/4885MAPT 4303/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | LMNA 3504/4885CYP3A4 261/4885MAPT 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.